Quercus Ilex & Quercus Robur Allergen Extracts Standardisation

Status Not yet recruiting

Clinical Trial Summary

The objective of this study is to determine the biological activity of Quercus illex and Quercus robur allergen extracts in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).

Clinical Trial Description

The trial will consist of a single visit, in which the following procedures will be carried out: - Demographic data. - Clinical history. - Inclusion/exclusion criteria. - General examination. - Performance of prick-tests (3 concentrations of Quercus ilex allergenic extract, 3 concentrations of Quercus robur allergenic extract, positive control and negative control). - Obtaining a blood sample from the patient to create a pool of sera for the "in vitro" standardization of the allergenic extract. This pool of sera is necessary for the characterization of the Company's standard. Each serum sample will be stored in a tube that will be labeled with the subject number and frozen. These serum samples will remain in the freezer until the study is completed. When the study is completed, they will be transported to the laboratory, where all sera will be pooled. This "pool" of sera will be used to perform the complementary in vitro standardization tests. These include ELISA for measurement of inhibition against specific IgE, etc. These serum samples are not destroyed. They are pooled together to form a pool that will be used, as described in the previous paragraph, in all the in vitro tests necessary to standardize and characterize this extract and produce its corresponding HIRP (In-house reference preparation), as indicated by the Royal Spanish Pharmacopoeia and the European Pharmacopoeia. This pool of sera is not destroyed, it is used in the in vitro analyses necessary for the standardization of new batches of this allergenic extract. Once the pool has been formed, the tubes containing the original serum samples are destroyed. - Evaluation of adverse events. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05532566
Study type	Interventional
Source	Inmunotek S.L.
Contact	Miguel Casanovas
Phone	912908942
Email	mcasanovas@inmunotek.com
Status	Not yet recruiting
Phase	N/A
Start date	January 2, 2023
Completion date	April 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04058743` - Nickel Sensitivity	N/A
Not yet recruiting	`NCT05649891` - Checklists Resuscitation Emergency Department	N/A
Active, not recruiting	`NCT05605795` - Investigation of Cross-allergies Between Cefazolin and Amoxicillin With Skin Tests and Provocation Test
Recruiting	`NCT06065137` - Standardised Drug Provocation Testing in Perioperative Hypersensitivity	N/A
Completed	`NCT04510376` - Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method	N/A
Completed	`NCT05185479` - Analysis of Adverse Events in Anesthesia Using Artificial Intelligence
Recruiting	`NCT05185362` - Epidemiology of Pecan Nut Allergy
Completed	`NCT03489694` - Repeatability and Reproducibility of Skin Test Endpoint Titration
Completed	`NCT03525496` - Interest of Challenge Tests for Diagnosis of Immediate Hypersensitivity Against Iodinated Contrast Agents
Completed	`NCT03942692` - What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction
Enrolling by invitation	`NCT05670756` - Preoperative Survey to Evaluate Patient Allergy
Recruiting	`NCT05462444` - Development of Personalized Balanced Nutrition Concept Through an IT Platform
Not yet recruiting	`NCT05284253` - Is There an Allergy to Pure Metallic Gold Microparticles?	N/A
Completed	`NCT03157505` - Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis	Phase 3
Completed	`NCT01436617` - Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab	Phase 2
Not yet recruiting	`NCT05533385` - Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.	N/A
Recruiting	`NCT06011603` - Prineo Sensitivity Dressing Study	Phase 4
Completed	`NCT04761822` - COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations	Phase 2
Recruiting	`NCT05367531` - Assessment of Injectable Medication Platforms	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Quercus Ilex and Quercus Robur Allergen Extracts Standardisation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms